HilleVax, Inc. (NASDAQ:HLVX – Get Rating) was the target of a large increase in short interest during the month of October. As of October 31st, there was short interest totalling 737,700 shares, an increase of 28.5% from the October 15th total of 574,100 shares. Based on an average daily trading volume, of 67,900 shares, the short-interest ratio is presently 10.9 days. Approximately 5.6% of the shares of the company are sold short.

Institutional Investors Weigh In On HilleVax

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Frazier Life Sciences Management L.P. bought a new position in HilleVax in the 2nd quarter worth $101,493,000. Deerfield Management Company L.P. Series C bought a new position in HilleVax in the 2nd quarter worth $28,614,000. Price T Rowe Associates Inc. MD bought a new position in HilleVax in the 2nd quarter worth $12,037,000. Franklin Resources Inc. bought a new position in HilleVax in the 2nd quarter worth $7,351,000. Finally, State Street Corp bought a new position in HilleVax in the 2nd quarter worth $1,794,000.

Get HilleVax alerts:

HilleVax Trading Down 7.9 %

Shares of NASDAQ:HLVX traded down $1.65 during midday trading on Friday, hitting $19.23. The company had a trading volume of 164,877 shares, compared to its average volume of 89,586. The company has a debt-to-equity ratio of 0.02, a current ratio of 25.54 and a quick ratio of 25.54. HilleVax has a 12-month low of $7.90 and a 12-month high of $24.42. The business has a fifty day simple moving average of $19.02.

HilleVax (NASDAQ:HLVX – Get Rating) last posted its quarterly earnings data on Wednesday, August 10th. The company reported ($2.03) EPS for the quarter, missing the consensus estimate of ($0.87) by ($1.16). Sell-side analysts forecast that HilleVax will post -8.23 EPS for the current year.

About HilleVax

(Get Rating)

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.

See Also

• Get a free copy of the StockNews.com research report on HilleVax (HLVX)
• MarketBeat: Week in Review 11/7 – 11/11
• Oil Is a Compelling Reason The Sell-Off In Stocks Isn't Over
• Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
• Six Flags is a Ride You Don't Want to Get Stuck On
• Vision Hydrogen, Now Vision Energy, Puts Hopes In Stock Split

Receive News & Ratings for HilleVax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HilleVax and related companies with MarketBeat.com's FREE daily email newsletter.